<head>
    <!-- Stylesheet -->
    <link rel="stylesheet" href="css/belief.css">
</head>
<!-- Main -->
<main>
    <div class="tabs">
        <a href="" ui-sref="INCLUSION-CRITERIA" class="tab tab--active">TRIAL DESIGN</a>
        <a href="" ui-sref="BASELINE-CHARACTERISTICS" class="tab">BASELINE CHARACTERISTICS</a>
    </div>
    <h2 class="primary">BELEODAQ Is for Adult Patients With PTCL at First or Subsequent Relapse<sup>1</sup></h2>
    <h3 class="secondary-variant">The BELIEF trial evaluated the overall response rate (ORR*) with BELEODAQ, a single-agent treatment regimen<sup>1,2</sup>
    </h3>
    <ul>
        <li>
            <h4 class="light">BELIEF was a single-arm, open-label, nonrandomized, international phase 2 study of 129 adult patients with R/R PTCL<sup>1,2</sup></h4>
        </li>
        <li>
            <h4 class="light">
                120 of the 129 had histologically confirmed PTCL and were evaluable for efficacy<sup>1</sup>
            </h4>
        </li>
        <li>
            <h4 class="light">
                The median time from PTCL diagnosis was 12.0 months (range, 2.6-266.4)<sup>2</sup>
            </h4>
        </li>
    </ul>
    <div class="tabs">
        <a href="" ui-sref="INCLUSION-CRITERIA" class="tab">INCLUSION CRITERIA</a>
        <a href="" ui-sref="EXCLUSION-CRITERIA" class="tab">EXCLUSION CRITERIA</a>
        <a href="" ui-sref="DOSING-OF-BELEODAQ" class="tab tab--active-variant">DOSING OF BELEODAQ</a>
        <a href="" ui-sref="PRIMARY-ENDPOINTS" class="tab">PRIMARY ENDPOINTS</a>
        <a href="" ui-sref="SECONDARY-ENDPOINTS" class="tab">SECONDARY ENDPOINTS</a>
        <a href="" ui-sref="STUDY-ASSESSMENT" class="tab">STUDY ASSESSMENT</a>
    </div>
    <div class="tab-content">
        <h4 class="light"><strong>1000 mg/m<sup>2</sup> by intravenous infusion over 30 minutes</strong> once daily on days 1-5 of a 21-day cycle<sup>2</sup>
        </h4>
        <ul>
            <li>
                <h4 class="light">Two dose reductions for hematologic and nonhematologic toxicity were permitted in 25% increments, after which BELEODAQ was discontinued</h4>
            </li>
            <li>
                <h4 class="light">Cycles were repeated every 3 weeks until PD, death, unacceptable toxicity, HSCT, loss to follow-up, or patient or investigator decision</h4>
            </li>
        </ul>
    </div>
    <p class="dark"><sup>*</sup>In the BELIEF trial, ORR included patients with a complete response and with a partial response.<sup>1,2</sup></p>
    <p class="light dark">AE, adverse event; ANC, absolute neutrophil count; BMB, bone marrow biopsies; CR, complete response; ECOG, Eastern Cooperative Oncology Group; HSCT, hematopoietic stem cell
        transplantation; IRC, independent review committee; IWG, International Working Group; ORR, overall response rate; PD, progressive disease; PR, partial response; PTCL, peripheral T-cell lymphoma; R/R relapsed/refractory; SAP, statistical analysis plan.</p>
    <div class="button-group">
        <a href="" ui-sref="ABOUT" class="button justify-left secondary"><i class="fas fa-chevron-left"></i> About BELEODAQ</a>
        <a href="" ui-sref="ORR" class="button justify-right">Efficacy <i class="fas fa-chevron-right"></i></a>
    </div>
</main>